New Agents and New Toxicities in Malignant Hematology: BCL2 Inhibitors, Anti-BCMA, and FLT3 Inhibitors
By: Nicole Ianniello, PharmD
New Agents and New Toxicities in Malignant Hematology: BCL2 Inhibitors, Anti-BCMA, and FLT3 Inhibitors
By: Nicole Ianniello, PharmD
Novel Approaches for Early Stages-Locally Advanced Esophageal and GE Junction Tumors
By: Pedro G. Solivan, MD
CLL: At Recurrence- What is the Best Therapy and What is Coming from the Bench Lab?
By: Saba S Nakhle - MD
Hematology Malignancies Session
By: Javier Pinilla-Ibarz, MD, PhD, Luis E. Fayad, MD, Sergio Giralt, MD, Mohamed A. Kharfan-Dabaja, MD, MBA, FACP
Panel Discussion: Practice Changing Developments in Benign and Malignant Hematology
By: Joseph Tuscano, MD
Indentification and Management of Tyrosine Kinase Inhibitors (TKIs) Toxicities
By: Josephine Previlon, MPAS, PA-C
New Agents and New Toxicities in Malignant Hematology: BCL2 Inhibitors, Anti-BCMA, and FLT3 Inhibitors
By: Nicole Ianniello, PharmD
Myelodysplastic Syndrome: Challenges, Current Standard Therapy and Future Directions
By: Rami Komrokji, MD
Myelodysplastic Syndrome: Challenges, Current Standard Therapy and Future Directions
By: Rami Komrokji, MD
